ABSTRACT
Background Even though anxious depression is among the most prevalent psychiatric conditions; its underlying neural and behavioral characteristics remain not well understood. This may be important to break down heterogeneity in depression. This study investigated the unique profile of individuals with anxious depression using affective startle modulation, a process known to independently probe appetitive/defensive systems and known to be affected by mood and anxiety disorders
Methods 236 depressed participants of the Tulsa 1000 study completed multi-level assessments including an emotional reactivity task with eye-blink startle measurement. To minimize bias due to covariates, 124 participants with comorbid depression and anxiety disorders (Dep+Anx) were matched with 62 participants with depression only (Dep). Eye-blink startle magnitudes during positive/negative visual cues were analyzed.
Results The Dep group showed no affective modulation of startle. However, the Dep+Anx group showed potentiation from aversive cues and attenuation from appetitive cues. The Dep+Anx group also showed increased attenuation from appetitive cues compared to the Dep group. Dimensionally, the effect of self-report anxiety on startle was moderated by self-report depression.
Conclusions Compared to individuals with depression, those with anxious depression demonstrate heightened positive/negative startle modulation, with depression levels moderating the link between anxiety sensitivity and startle reflex. The differences between these groups in processing aversive/appetitive information support the conclusion that these depression subtypes should be considered separately in future clinical trials. ClinicalTrials.gov identifier: #NCT02450240.
General scientific summary This study suggests that there are striking differences between those with anxious and non-anxious depression. Specifically, these two groups differ in terms of threat reactivity measured by eye-blink startle response. This proposes that the two groups be separated in future clinical trials.
Competing Interest Statement
Dr. Paulus is an advisor to Spring Care, Inc., a behavioral health startup, he has received royalties for an article about methamphetamine in UpToDate; Dr. Ironside reports no financial relationships with commercial interests; Dr. Kuplicki reports no financial relationships with commercial interests; Ms. Walker reports no financial relationships with commercial interests; Mr. Poplin reports no financial relationships with commercial interests; Ms. Ramsey reports no financial relationships with commercial interests; Ms. Forthman reports no financial relationships with commercial interests; Ms. Nestor reports no financial relationships with commercial interests; Dr. Aupperle reports no financial relationships with commercial interests; Dr. Guinjoan reports no financial relationships with commercial interests; Dr. Khalsa reports no financial relationships with commercial interests; Dr. Savitz reports no financial relationships with commercial interests; Dr. Stewart reports no financial relationships with commercial interests; Dr. Victor reports no financial relationships with commercial interests.
Funding Statement
This work has been supported in part by The William K. Warren Foundation and the National Institute of General Medical Sciences Center Grant Award Number 1P20GM121312. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The ClinicalTrials.gov identifier for the clinical protocol associated with data published in the current paper is NCT02450240, Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from Western Institutional Review Board T1000 protocol #20142082.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures: Dr. Paulus is an advisor to Spring Care, Inc., a behavioral health startup, he has received royalties for an article about methamphetamine in UpToDate; Dr. Ironside reports no financial relationships with commercial interests; Dr. Kuplicki reports no financial relationships with commercial interests; Ms. Walker reports no financial relationships with commercial interests; Ms. Ramsey reports no financial relationships with commercial interests; Ms. Forthman reports no financial relationships with commercial interests; Ms. Nestor reports no financial relationships with commercial interests; Dr. Aupperle reports no financial relationships with commercial interests; Dr. Guinjoan reports no financial relationships with commercial interests; Dr. Khalsa reports no financial relationships with commercial interests; Dr. Savitz reports no financial relationships with commercial interests; Dr. Stewart reports no financial relationships with commercial interests; Dr. Victor reports no financial relationships with commercial interests.
This manuscript added justification of the comparison between two clinical groups because of healthy comparisons lying in the middle of the two clinical groups in terms of hyperarousal. HRV analysis was also added to this revision and the associated co-author added.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
